David Nierengarten
Stock Analyst at Wedbush
(4.38)
# 354
Out of 5,090 analysts
209
Total ratings
52.94%
Success rate
17.85%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics | Reiterates: Outperform | $25 | $11.45 | +118.44% | 2 | Nov 25, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $880 → $1,000 | $916.31 | +9.13% | 23 | Nov 14, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $9 → $7 | $9.77 | -28.32% | 11 | Nov 7, 2025 | |
| FATE Fate Therapeutics | Upgrades: Outperform | $5 → $7 | $1.11 | +533.48% | 16 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $90 → $110 | $93.70 | +17.40% | 4 | Oct 17, 2025 | |
| ANAB AnaptysBio | Maintains: Outperform | $45 → $70 | $43.05 | +62.60% | 14 | Oct 15, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $38 → $44 | $41.10 | +7.06% | 4 | Oct 13, 2025 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $6 | $8.31 | -27.80% | 11 | Oct 13, 2025 | |
| NUVL Nuvalent | Reiterates: Outperform | $115 | $107.05 | +7.43% | 6 | Sep 8, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $2.99 | +33.78% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $18.05 | +44.04% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $9.74 | +125.87% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $7 | $5.29 | +32.33% | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $8.31 | -3.67% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.39 | +360.25% | 4 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $27 | $11.75 | +129.89% | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $20.12 | +64.02% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $8.81 | +127.01% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $18.86 | +64.41% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $75.40 | +19.36% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $45.35 | +3.64% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $11.41 | +75.28% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $30.94 | +29.28% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $33.55 | +34.13% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.09 | +817.43% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $3.68 | +389.13% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $39.36 | -74.59% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.85 | +211.69% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $29.01 | +96.48% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $27.42 | +538.22% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.00 | +16,566.67% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $5.89 | +918.68% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $7.69 | +147.07% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $36.60 | +104.92% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.11 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.34 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.30 | - | 3 | Nov 20, 2017 |
BridgeBio Oncology Therapeutics
Nov 25, 2025
Reiterates: Outperform
Price Target: $25
Current: $11.45
Upside: +118.44%
argenx SE
Nov 14, 2025
Maintains: Outperform
Price Target: $880 → $1,000
Current: $916.31
Upside: +9.13%
Intellia Therapeutics
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $9.77
Upside: -28.32%
Fate Therapeutics
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.11
Upside: +533.48%
Disc Medicine
Oct 17, 2025
Maintains: Outperform
Price Target: $90 → $110
Current: $93.70
Upside: +17.40%
AnaptysBio
Oct 15, 2025
Maintains: Outperform
Price Target: $45 → $70
Current: $43.05
Upside: +62.60%
Kiniksa Pharmaceuticals International,
Oct 13, 2025
Maintains: Outperform
Price Target: $38 → $44
Current: $41.10
Upside: +7.06%
Nuvation Bio
Oct 13, 2025
Reiterates: Outperform
Price Target: $6
Current: $8.31
Upside: -27.80%
Nuvalent
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $107.05
Upside: +7.43%
Shattuck Labs
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $2.99
Upside: +33.78%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $18.05
Upside: +44.04%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $9.74
Upside: +125.87%
Aug 13, 2025
Downgrades: Neutral
Price Target: $7
Current: $5.29
Upside: +32.33%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $8.31
Upside: -3.67%
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $2.39
Upside: +360.25%
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $11.75
Upside: +129.89%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $20.12
Upside: +64.02%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $8.81
Upside: +127.01%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $18.86
Upside: +64.41%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $75.40
Upside: +19.36%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $45.35
Upside: +3.64%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $11.41
Upside: +75.28%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $30.94
Upside: +29.28%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $33.55
Upside: +34.13%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.09
Upside: +817.43%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $3.68
Upside: +389.13%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $39.36
Upside: -74.59%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.85
Upside: +211.69%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $29.01
Upside: +96.48%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $27.42
Upside: +538.22%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.00
Upside: +16,566.67%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $5.89
Upside: +918.68%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $7.69
Upside: +147.07%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $36.60
Upside: +104.92%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.11
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.34
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $11.30
Upside: -